Cell-Easy, a French CDMO focused on advanced cell therapies, and the Toulouse University Hospital, obtained IMPD (Investigational Medicinal Product Dossier) approval from the European Medicines Agency for a first-in-human clinical trial. The trial will use an allogeneic treatment developed from an autologous process for patients with ischemic digital ulcers in systemic sclerosis. Cell-Easy developed the manufacturing process from an initially autologous one where the cell donor was the patient h...